Mid Term Report: A Year in Japan

Therapeutic Drug Monitoring in Clinical Chemistry: A Comparative Study of Japan and Switzerland



Scholarship Recipient Autumn 2024

Vanessa Gantenbein

SJCC

SCCIJ
Swiss Chamber of Commerce and Industry in Japan

Kobe, March 2025

Acknowledgment

I would like to express my sincere gratitude to the Swiss-Japan Scholarship Fund, particularly to the Scholarship Committee members, **Jacqueline Tschumi** (Chairperson) and **Wieland Noetzold** (Treasurer SJCC), for selecting me as a recipient of this prestigious award. Their trust and support have enabled me to embark on this enriching journey in Japan, enhancing my cultural understanding and professional skills. I am deeply appreciative of this opportunity and the role they play in fostering Swiss-Japanese relations.

Table of Contents

1. Introduction

In modern healthcare, ensuring that patients receive the correct medication at the appropriate dosage is crucial for effective treatment. Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug concentrations in a patient's blood to optimise therapeutic outcomes while minimising toxicity. This practice is especially important for medications with narrow therapeutic indices, where small changes in dosage can lead to significant variations in efficacy and safety.

This report explores TDM practices in Japan and Switzerland, two countries celebrated for their advanced healthcare systems. For me, this project is not merely academic; it's a convergence of lifelong passions. My journey has been shaped by a deep yearning to experience Japanese culture and contribute to the global biomedical community. Thanks to the Swiss-Japanese Chamber of Commerce's "Year in Japan" program, I now have the incredible opportunity to immerse myself in the Japanese language and society firsthand. As I dedicate my efforts to language acquisition, I also aim to explore how Japan's unique cultural perspectives influence its approach to healthcare and technological innovation. Although my focus is currently on language studies, I hope to leverage publicly available resources to examine TDM practices in both countries, seeking to understand the distinct challenges and potential areas for collaboration between Switzerland and Japan. This report, therefore, is the first step in what I hope will be a long-term exploration of the intersection of science and culture in Japan.

2. Background on TDM

Before delving into country-specific practices, it's crucial to understand what TDM is, its historical development, and why it plays a vital role in patient care. This section covers these fundamental aspects.

2.1 Definition and Importance

TDM is defined as the clinical practice of measuring specific drugs at designated intervals to maintain drug concentrations within a therapeutic range: high enough to be effective but low enough to avoid toxicity (Figure 1).

TDM is essential for several reasons:

- Prevention of Adverse Effects: Regular monitoring can identify potential toxicity before it becomes severe.
- Enhanced Efficacy: Ensuring optimal drug levels improves treatment outcomes.
- Individualised Therapy: It allows healthcare providers to tailor treatment plans based on individual patient needs.

Commonly monitored drugs include anticoagulants like warfarin, antiepileptics such as phenytoin, mood stabilizers like lithium, and antibiotics such as vancomycin.



Figure 1: Overview of TDM workflow

2.2 Historical Context

Historically, TDM has evolved alongside advancements in pharmacology and clinical chemistry. The practice gained prominence in the late 20th century as more medications with narrow therapeutic indices became available. Early studies highlighted the importance of monitoring levels of drugs like digoxin (cardiac glycosides) and aminoglycosides (antibiotic), paving the way for broader applications of TDM in clinical settings.

3. TDM Practices in Japan

Japan has developed a unique approach to TDM, influenced by its healthcare system and cultural factors. This section explores how TDM is implemented, regulated, and practiced in Japanese healthcare settings.

3.1 Overview

In Japan, TDM has become increasingly recognised as a key component of personalised medicine. The Japanese Society of Clinical Chemistry (JSCC) provides guidelines that standardise practices across hospitals and clinics.

3.2 Regulatory Framework

The Pharmaceuticals and Medical Devices Agency (PMDA) governs the regulatory landscape for pharmaceuticals in Japan. The PMDA sets stringent standards for laboratory practices, ensuring that TDM is conducted according to established protocols. This focus on quality helps maintain high standards across clinical laboratories.

3.3 Implementation of TDM

Japanese hospitals have effectively integrated TDM into their clinical practices. For example, monitoring vancomycin levels has been shown to significantly reduce the risk of nephrotoxicity while ensuring effective treatment of infections.

3.4 Challenges

Despite these advancements, challenges remain in implementing TDM widely across all healthcare facilities in Japan. Variability in laboratory capabilities and access to resources can hinder consistent implementation across different healthcare settings. Additionally, gaps in training or awareness among healthcare professionals regarding the importance of TDM may affect its utilisation.

Cultural factors may also influence how healthcare providers approach patient education about TDM. Patients may not fully understand the necessity or implications of regular monitoring, which could impact adherence to treatment plans.

4. TDM Practices in Switzerland

Switzerland, known for its advanced healthcare system, has its own distinct approach to TDM. This section examines the Swiss perspective on TDM, including regulatory frameworks and innovative practices.

4.1 Overview

Switzerland prioritises TDM within its healthcare framework as well. The Swiss Society of Clinical Chemistry (SSCC) provides comprehensive guidelines that align with international standards for monitoring practices.

4.2 Regulatory Standards

In Switzerland, while the Swiss Federal Office of Public Health (FOPH) oversees general public health matters, Swissmedic (Swiss Agency for Therapeutic Products) is the primary regulatory body for pharmaceuticals and medical devices. This regulatory environment encourages adherence to high standards while allowing flexibility for innovation; a crucial aspect given the rapid advancements in medical science.

Switzerland's regulatory framework supports collaboration between various stakeholders, including hospitals, laboratories, and pharmaceutical companies, fostering an environment conducive to research and development.

4.3 Integration of Pharmacogenomics

A notable aspect of Swiss TDM practices is the integration of pharmacogenomics (the study of how genes affect a person's response to drugs) into routine monitoring . By considering genetic variations that influence drug metabolism, Swiss healthcare providers can develop more personalised treatment plans that enhance efficacy and minimise adverse effects (Figure 2).



Figure 2: Pharmacogenomic Status: Four Clinically Actionable Groups (Benefical, Not Beneficial, Toxic, Not Toxic)

For instance, genetic testing can identify patients who are poor metabolisers of certain medications like clopidogrel (anticoagulant) or warfarin, allowing clinicians to adjust dosages accordingly.

5. Comparative Analysis

Having explored TDM practices in both Japan and Switzerland, this section draws comparisons, highlighting similarities and differences in approaches and outcomes.

5.1 Similarities

Both Japan and Switzerland demonstrate a strong commitment to effective TDM practices:

- Both countries monitor similar classes of drugs with narrow therapeutic indices.
- Regulatory bodies emphasise quality assurance and adherence to established guidelines.

5.2 Differences

However, there are notable differences:

- Cultural Attitudes: Japan generally adopts a more conservative approach to drug monitoring, relying heavily on established protocols. In contrast, Switzerland actively incorporates pharmacogenomic data into its practices.
- Regulatory Flexibility: Switzerland's regulations allow for more adaptability in integrating new research findings compared to Japan's more stringent adherence to existing guidelines.

5.3 Impact on Patient Care

These differences have real implications for patient care; patients in Switzerland may benefit from more personalised treatment plans due to pharmacogenomics integration while Japanese patients might experience more consistent adherence to established monitoring protocols.

6. Future Directions

As both countries continue to advance their healthcare systems, several future directions could enhance TDM practices:

- Increased Use of Technology: The integration of digital health technologies could streamline data collection and analysis for TDM.
- Education and Training: Ongoing education for healthcare professionals about the importance and implementation of TDM will be crucial.
- Research Collaboration: Collaborative research initiatives between Japan and Switzerland could foster knowledge exchange regarding best practices in TDM (Figure 3).



Figure 3: Symbol for Swiss-Japanese Collaboration

7. Conclusion

In summary, TDM represents a crucial aspect of clinical chemistry that enhances patient care through optimised drug therapy. Both Japan and Switzerland have developed robust frameworks for TDM; however, their methodologies reflect different cultural attitudes toward regulation and innovation in healthcare practices. As we move forward into an era where personalised medicine becomes increasingly important, integrating emerging technologies and pharmacogenomic data into TDM protocols will be essential for improving patient outcomes across both countries.

8. References

- Aonuma, K., Shiga, T., Atarashi, H., Doki, K., Echizen, H., Hagiwara, N., Hasegawa, J., Hayashi, H., Hirao, K., Ichida, F., Ikeda, T., Maeda, Y., Matsumoto, N., Sakaeda, T., Shimizu, W., Sugawara, M., Totsuka, K., Tsuchishita, Y., Ueno, K., Watanabe, E., … Japanese Circulation Society and the Japanese Society of Therapeutic Drug Monitoring Joint Working Group (2017). Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015) - Digest Version. Circulation journal : official journal of the Japanese Circulation Society, 81(4), 581–612. https://doi.org/10.1253/circj.CJ-66-0138
- Buclin, T., Thoma, Y., Widmer, N., André, P., Guidi, M., Csajka, C., & Decosterd, L. A. (2020). The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib. Frontiers in pharmacology, 11, 177. https://doi.org/10.3389/fphar.2020.00177
- Ebihara, F., Hamada, Y., Kato, H., Maruyama, T., & Kimura, T. (2022). Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan. International Journal of Environmental Research and Public Health, 19(5), 2516. https://doi.org/10.3390/ijerph19052516
- Hamzic, S., Aebi, S., Joerger, M., Montemurro, M., Ansari, M., Amstutz, U., & Largiadèr, C. (2020). Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. Swiss Medical Weekly, 150(4748), w20375. https://doi.org/10.4414/smw.2020.20375
- Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., … Baumann, P. (2018). Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 51(01/02), e1–e1. https://doi:10.1055/s-0037-1600991
- Imai, S., Momo, K., Kashiwagi, H. et al. Association of the ward pharmacy service with active implementation of therapeutic drug monitoring for vancomycin and teicoplanin—an epidemiological surveillance study using Japanese large health insurance claims database. J Pharm Health Care Sci 6, 18 (2020). https://doi.org/10.1186/s40780-020-00174-8
- Matsumoto, K., Oda, K., Shoji, K., Hanai, Y., Takahashi, Y., Fujii, S., Hamada, Y., Kimura, T., Mayumi, T., Ueda, T., Nakajima, K., & Takesue, Y. (2022). Clinical Practice Guidelines

for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics, 14(3), 489. https://doi.org/10.3390/pharmaceutics14030489

- Rentsch, K., Fathi, M., Grignaschi, N., Magnin, J. L., Printzen, G., Thormann, W., … Werner, D. (2005). Monographies on drugs, which are frequently analysed in the course of Therapeutic Drug Monitoring Monographien über Medikamente, die regelmässig im Rahmen des Therapeutic Drug Monitorings analysiert werden. LaboratoriumsMedizin, 29(4), 287–297. https://doi:10.1515/jlm.2005.040
- Takesue, Y., Hanai, Y., Oda, K., Hamada, Y., Ueda, T., Mayumi, T., Matsumoto, K., Fujii, S., Takahashi, Y., Miyazaki, Y., Kimura, T., & Japanese Antimicrobial Therapeutic Drug Monitoring Guideline Committee (2022). Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Clinical therapeutics, 44(12), 1604–1623. https://doi.org/10.1016/j.clinthera.2022.10.005

9. List of Figures